These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 29650277)

  • 41. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
    Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
    Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism.
    Shih JW; Wang LY; Hung CL; Kung HJ; Hsieh CL
    Int J Mol Sci; 2015 Dec; 16(12):28943-78. PubMed ID: 26690121
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular alterations and emerging targets in castration resistant prostate cancer.
    Lorente D; De Bono JS
    Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives.
    Hu J; Wang G; Sun T
    Tumour Biol; 2017 May; 39(5):1010428317692259. PubMed ID: 28475016
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.
    Hotte SJ
    Future Oncol; 2017 Feb; 13(4):369-379. PubMed ID: 27712093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dissecting major signaling pathways in prostate cancer development and progression: Mechanisms and novel therapeutic targets.
    Ramalingam S; Ramamurthy VP; Njar VCO
    J Steroid Biochem Mol Biol; 2017 Feb; 166():16-27. PubMed ID: 27481707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological Evolution of Castration-resistant Prostate Cancer.
    Davies A; Conteduca V; Zoubeidi A; Beltran H
    Eur Urol Focus; 2019 Mar; 5(2):147-154. PubMed ID: 30772358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now?
    Tsaur I; Heidegger I; Kretschmer A; Borgmann H; Gandaglia G; Briganti A; de Visschere P; Mathieu R; Valerio M; van den Bergh R; Ost P; Mirvald C; Tilki D; Ploussard G; Surcel C;
    Cancer Treat Rev; 2019 May; 75():20-26. PubMed ID: 30875581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
    Uemura H
    Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The molecular biology of prostate cancer: current understanding and clinical implications.
    Gandhi J; Afridi A; Vatsia S; Joshi G; Joshi G; Kaplan SA; Smith NL; Khan SA
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):22-36. PubMed ID: 29282359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strategies for targeting the androgen receptor axis in prostate cancer.
    Carver BS
    Drug Discov Today; 2014 Sep; 19(9):1493-7. PubMed ID: 25107669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Re: Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Taneja SS
    J Urol; 2015 Sep; 194(3):704. PubMed ID: 26292859
    [No Abstract]   [Full Text] [Related]  

  • 56. [AR-V7 as a predictive biomarker for prostate cancer-more than just prophecy].
    Bernemann C; Krabbe LM
    Urologe A; 2020 Jan; 59(1):80-83. PubMed ID: 31820021
    [No Abstract]   [Full Text] [Related]  

  • 57. Mechanisms of Therapeutic Resistance in Prostate Cancer.
    Nakazawa M; Paller C; Kyprianou N
    Curr Oncol Rep; 2017 Feb; 19(2):13. PubMed ID: 28229393
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer.
    Mollica V; Di Nunno V; Cimadamore A; Lopez-Beltran A; Cheng L; Santoni M; Scarpelli M; Montironi R; Massari F
    Cells; 2019 Jan; 8(1):. PubMed ID: 30642011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomarkers in prostate cancer - Current clinical utility and future perspectives.
    Kretschmer A; Tilki D
    Crit Rev Oncol Hematol; 2017 Dec; 120():180-193. PubMed ID: 29198331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Has the Time Arrived for Biomarker-Directed Therapy in Castration-Resistant Prostate Cancer?
    Taplin ME; Balk SP
    JAMA Oncol; 2015 Aug; 1(5):577-9. PubMed ID: 26181796
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.